首例使用嵌合抗原受体t细胞免疫疗法治疗高风险阴燃性多发性骨髓瘤的病例报告。

IF 4.7 2区医学 Q1 MEDICINE, GENERAL & INTERNAL

Journal of Translational Internal Medicine Pub Date : 2023-09-01 DOI:10.2478/jtim-2023-0097

Yang Liu, Wenbing Duan, Xiaojun Huang, Jin Lu

{"title":"首例使用嵌合抗原受体t细胞免疫疗法治疗高风险阴燃性多发性骨髓瘤的病例报告。","authors":"Yang Liu, Wenbing Duan, Xiaojun Huang, Jin Lu","doi":"10.2478/jtim-2023-0097","DOIUrl":null,"url":null,"abstract":"Smoldering multiple myeloma (SMM) is now considered a heterogeneous set of diseases with different tendencies to progress to active myeloma. Several trials aimed at curing multiple myeloma (MM) in the smoldering stage through intensive treatment have reported effective control of active myeloma.[1] At the same time, Chimeric antigen receptor (CAR) T-cell immunotherapy is currently being intensively tested for treating relapsed and refractory myeloma.[2] Here, we report a patient with smoldering myeloma who elected to be treated with CAR T-cell therapy and has now achieved minimal residual disease (MRD) negativity.","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"11 3","pages":"294-296"},"PeriodicalIF":4.7000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474885/pdf/","citationCount":"0","resultStr":"{\"title\":\"A first case report of using chimeric antigen receptor T-cell immunotherapy to treat high-risk smoldering multiple myeloma.\",\"authors\":\"Yang Liu, Wenbing Duan, Xiaojun Huang, Jin Lu\",\"doi\":\"10.2478/jtim-2023-0097\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Smoldering multiple myeloma (SMM) is now considered a heterogeneous set of diseases with different tendencies to progress to active myeloma. Several trials aimed at curing multiple myeloma (MM) in the smoldering stage through intensive treatment have reported effective control of active myeloma.[1] At the same time, Chimeric antigen receptor (CAR) T-cell immunotherapy is currently being intensively tested for treating relapsed and refractory myeloma.[2] Here, we report a patient with smoldering myeloma who elected to be treated with CAR T-cell therapy and has now achieved minimal residual disease (MRD) negativity.\",\"PeriodicalId\":51339,\"journal\":{\"name\":\"Journal of Translational Internal Medicine\",\"volume\":\"11 3\",\"pages\":\"294-296\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474885/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Translational Internal Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2478/jtim-2023-0097\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Translational Internal Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2478/jtim-2023-0097","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

A first case report of using chimeric antigen receptor T-cell immunotherapy to treat high-risk smoldering multiple myeloma.

查看原文本刊更多论文

A first case report of using chimeric antigen receptor T-cell immunotherapy to treat high-risk smoldering multiple myeloma.

Smoldering multiple myeloma (SMM) is now considered a heterogeneous set of diseases with different tendencies to progress to active myeloma. Several trials aimed at curing multiple myeloma (MM) in the smoldering stage through intensive treatment have reported effective control of active myeloma.[1] At the same time, Chimeric antigen receptor (CAR) T-cell immunotherapy is currently being intensively tested for treating relapsed and refractory myeloma.[2] Here, we report a patient with smoldering myeloma who elected to be treated with CAR T-cell therapy and has now achieved minimal residual disease (MRD) negativity.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Translational Internal Medicine MEDICINE, GENERAL & INTERNAL-

CiteScore

5.50

自引率

8.20%

发文量